Energenesis BiomedicalLTD Past Earnings Performance
Past criteria checks 0/6
Energenesis BiomedicalLTD's earnings have been declining at an average annual rate of -16.7%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been growing at an average rate of 3% per year.
Key information
-16.7%
Earnings growth rate
-9.4%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 3.0% |
| Return on equity | -37.8% |
| Net Margin | -3,296.2% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How Energenesis BiomedicalLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 7 | -244 | 82 | 180 |
| 30 Jun 24 | 7 | -199 | 83 | 137 |
| 31 Mar 24 | 7 | -247 | 85 | 179 |
| 31 Dec 23 | 7 | -260 | 82 | 185 |
| 30 Sep 23 | 7 | -244 | 77 | 180 |
| 30 Jun 23 | 8 | -318 | 72 | 256 |
| 31 Mar 23 | 8 | -291 | 65 | 239 |
| 31 Dec 22 | 7 | -266 | 63 | 214 |
| 30 Sep 22 | 7 | -257 | 68 | 200 |
| 30 Jun 22 | 7 | -167 | 69 | 108 |
| 31 Mar 22 | 6 | -124 | 67 | 64 |
| 31 Dec 21 | 7 | -120 | 66 | 62 |
| 30 Sep 21 | 7 | -115 | 60 | 63 |
| 30 Jun 21 | 8 | -117 | 60 | 66 |
| 31 Mar 21 | 7 | -123 | 63 | 69 |
| 31 Dec 20 | 7 | -129 | 66 | 72 |
| 30 Sep 20 | 7 | -140 | 66 | 83 |
| 30 Jun 20 | 7 | -151 | 66 | 94 |
| 31 Mar 20 | 6 | -151 | 62 | 96 |
| 31 Dec 19 | 6 | -150 | 59 | 98 |
| 30 Sep 19 | 5 | -138 | 58 | 86 |
| 30 Jun 19 | 5 | -125 | 57 | 75 |
| 31 Mar 19 | 5 | -115 | 53 | 69 |
| 31 Dec 18 | 5 | -105 | 49 | 63 |
| 30 Sep 18 | 5 | -95 | 42 | 60 |
| 30 Jun 18 | 6 | -85 | 36 | 57 |
| 31 Mar 18 | 6 | -78 | 32 | 52 |
| 31 Dec 17 | 5 | -71 | 28 | 48 |
| 31 Dec 16 | 6 | -35 | 13 | 26 |
| 31 Dec 15 | 2 | -15 | 5 | 12 |
Quality Earnings: 6657 is currently unprofitable.
Growing Profit Margin: 6657 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6657 is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.
Accelerating Growth: Unable to compare 6657's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6657 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.8%).
Return on Equity
High ROE: 6657 has a negative Return on Equity (-37.84%), as it is currently unprofitable.